Gregory K Friedman1, Blake P Moore1, Li Nan1, Virginia M Kelly1, Tina Etminan1, Catherine P Langford1, Hui Xu1, Xiaosi Han1, James M Markert1, Elizabeth A Beierle1, G Yancey Gillespie1. 1. Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham (UAB), Birmingham, Alabama (G.K.F., B.P.M., L.N., V.M.K.); Science and Technology Honors Program, Department of Chemistry, University of Alabama at Birmingham, Birmingham, Alabama (T.E.); Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama (C.P.L., J.M.M., G.Y.G.); Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama (H.X.); Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama (X.H.); Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama (E.A.B.).
Abstract
BACKGROUND: Childhood medulloblastoma is associated with significant morbidity and mortality that is compounded by neurotoxicity for the developing brain caused by current therapies, including surgery, craniospinal radiation, and chemotherapy. Innate therapeutic resistance of some aggressive pediatric medulloblastoma has been attributed to a subpopulation of cells, termed cancer-initiating cells or cancer stemlike cells (CSCs), marked by the surface protein CD133 or CD15. Brain tumors characteristically contain areas of pathophysiologic hypoxia, which has been shown to drive the CSC phenotype leading to heightened invasiveness, angiogenesis, and metastasis. Novel therapies that target medulloblastoma CSCs are needed to improve outcomes and decrease toxicity. We hypothesized that oncolytic engineered herpes simplex virus (oHSV) therapy could effectively infect and kill pediatric medulloblastoma cells, including CSCs marked by CD133 or CD15. METHODS: Using 4 human pediatric medulloblastoma xenografts, including 3 molecular subgroup 3 tumors, which portend worse patient outcomes, we determined the expression of CD133, CD15, and the primary HSV-1 entry molecule nectin-1 (CD111) by fluorescence activated cell sorting (FACS) analysis. Infectability and cytotoxicity of clinically relevant oHSVs (G207 and M002) were determined in vitro and in vivo by FACS, immunofluorescent staining, cytotoxicity assays, and murine survival studies. RESULTS: We demonstrate that hypoxia increased the CD133+ cell fraction, while having the opposite effect on CD15 expression. We established that all 4 xenografts, including the CSCs, expressed CD111 and were highly sensitive to killing by G207 or M002. CONCLUSIONS: Pediatric medulloblastoma, including Group 3 tumors, may be an excellent target for oHSV virotherapy, and a clinical trial in medulloblastoma is warranted.
BACKGROUND: Childhood medulloblastoma is associated with significant morbidity and mortality that is compounded by neurotoxicity for the developing brain caused by current therapies, including surgery, craniospinal radiation, and chemotherapy. Innate therapeutic resistance of some aggressive pediatric medulloblastoma has been attributed to a subpopulation of cells, termed cancer-initiating cells or cancer stemlike cells (CSCs), marked by the surface protein CD133 or CD15. Brain tumors characteristically contain areas of pathophysiologic hypoxia, which has been shown to drive the CSC phenotype leading to heightened invasiveness, angiogenesis, and metastasis. Novel therapies that target medulloblastoma CSCs are needed to improve outcomes and decrease toxicity. We hypothesized that oncolytic engineered herpes simplex virus (oHSV) therapy could effectively infect and kill pediatric medulloblastoma cells, including CSCs marked by CD133 or CD15. METHODS: Using 4 human pediatric medulloblastoma xenografts, including 3 molecular subgroup 3 tumors, which portend worse patient outcomes, we determined the expression of CD133, CD15, and the primary HSV-1 entry molecule nectin-1 (CD111) by fluorescence activated cell sorting (FACS) analysis. Infectability and cytotoxicity of clinically relevant oHSVs (G207 and M002) were determined in vitro and in vivo by FACS, immunofluorescent staining, cytotoxicity assays, and murine survival studies. RESULTS: We demonstrate that hypoxia increased the CD133+ cell fraction, while having the opposite effect on CD15 expression. We established that all 4 xenografts, including the CSCs, expressed CD111 and were highly sensitive to killing by G207 or M002. CONCLUSIONS:Pediatric medulloblastoma, including Group 3 tumors, may be an excellent target for oHSV virotherapy, and a clinical trial in medulloblastoma is warranted.
Authors: Lisa Diller; Eric J Chow; James G Gurney; Melissa M Hudson; Nina S Kadin-Lottick; Toana I Kawashima; Wendy M Leisenring; Lillian R Meacham; Ann C Mertens; Daniel A Mulrooney; Kevin C Oeffinger; Roger J Packer; Leslie L Robison; Charles A Sklar Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Gregory K Friedman; Marilyn C Haas; Virginia M Kelly; James M Markert; George Yancey Gillespie; Kevin A Cassady Journal: Transl Oncol Date: 2012-06-01 Impact factor: 4.243
Authors: V Papanastassiou; R Rampling; M Fraser; R Petty; D Hadley; J Nicoll; J Harland; R Mabbs; M Brown Journal: Gene Ther Date: 2002-03 Impact factor: 5.250
Authors: James M Markert; Shantanu N Razdan; Hui-Chien Kuo; Alan Cantor; Anette Knoll; Matthias Karrasch; L Burt Nabors; Michael Markiewicz; Bonita S Agee; Jennifer M Coleman; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; Ralph R Weichselbaum; John B Fiveash; G Yancey Gillespie Journal: Mol Ther Date: 2014-02-27 Impact factor: 11.454
Authors: X M He; C J Wikstrand; H S Friedman; S H Bigner; S Pleasure; J Q Trojanowski; D D Bigner Journal: Lab Invest Date: 1991-06 Impact factor: 5.662
Authors: Gregory K Friedman; Catherine P Langford; Jennifer M Coleman; Kevin A Cassady; Jacqueline N Parker; James M Markert; G Yancey Gillespie Journal: J Neurooncol Date: 2009-06-12 Impact factor: 4.130
Authors: G K Friedman; L Nan; M C Haas; V M Kelly; B P Moore; C P Langford; H Xu; X Han; E A Beierle; J M Markert; K A Cassady; G Y Gillespie Journal: Gene Ther Date: 2014-11-27 Impact factor: 5.250
Authors: Alicia M Waters; James M Johnston; Alyssa T Reddy; John Fiveash; Avi Madan-Swain; Kara Kachurak; Asim K Bag; G Yancey Gillespie; James M Markert; Gregory K Friedman Journal: Hum Gene Ther Clin Dev Date: 2017-03 Impact factor: 5.032
Authors: Evan F Garner; Laura L Stafman; Adele P Williams; Jamie M Aye; Caroline Goolsby; Venkatram R Atigadda; Blake P Moore; Li Nan; Jerry E Stewart; Anita B Hjelmeland; Gregory K Friedman; Elizabeth A Beierle Journal: J Neurooncol Date: 2018-08-21 Impact factor: 4.130
Authors: Gregory K Friedman; James M Johnston; Asim K Bag; Joshua D Bernstock; Rong Li; Inmaculada Aban; Kara Kachurak; Li Nan; Kyung-Don Kang; Stacie Totsch; Charles Schlappi; Allison M Martin; Devang Pastakia; Rene McNall-Knapp; Sameer Farouk Sait; Yasmin Khakoo; Matthias A Karajannis; Karina Woodling; Joshua D Palmer; Diana S Osorio; Jeffrey Leonard; Mohamed S Abdelbaki; Avi Madan-Swain; T Prescott Atkinson; Richard J Whitley; John B Fiveash; James M Markert; G Yancey Gillespie Journal: N Engl J Med Date: 2021-04-10 Impact factor: 91.245
Authors: Joshua D Bernstock; Zachary Wright; Asim K Bag; Florian Gessler; George Yancey Gillespie; James M Markert; Gregory K Friedman; James M Johnston Journal: World Neurosurg Date: 2018-11-24 Impact factor: 2.104
Authors: Joshua D Bernstock; Asim K Bag; John Fiveash; Kara Kachurak; Galal Elsayed; Gustavo Chagoya; Florian Gessler; Pablo A Valdes; Avi Madan-Swain; Richard Whitley; James M Markert; G Yancey Gillespie; James M Johnston; Gregory K Friedman Journal: Hum Gene Ther Date: 2020-08-17 Impact factor: 5.695
Authors: Zahraa F Audi; Zahraa Saker; Mahdi Rizk; Hisham F Bahmad; Sanaa M Nabha; Hayat Harati; Youssef Fares Journal: Curr Treat Options Oncol Date: 2021-07-30